Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

Vaccine

Volumn 25, Issue 21, 2007, Pages 4223-4234

  Lemesre, Jean Loup ^a   Holzmuller, Philippe ^a   Gonçalves, Rachel Bras ^a   Bourdoiseau, Gilles ^b   Hugnet, Christophe ^c   Cavaleyra, Mireille ^a   Papierok, Gérard ^d  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b VETAGRO SUP   (France)

^c CLINIQUE VÉTÉRINAIRE   (France)

^d Bio Véto Test ^*  (France)

Author keywords

Canine visceral leishmaniasis; Excreted secreted antigens; Immune responses; LiESAp MDP vaccine; Protection

Indexed keywords

IMMUNOGLOBULIN G2; LEISHMANIA VACCINE;

ARTICLE; DOG; FRANCE; IMMUNIZATION; IMMUNOFLUORESCENCE; LEISHMANIA INFANTUM; LEISHMANIASIS; LYMPHOCYTE; MACROPHAGE; NONHUMAN; PARASITOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMASTIGOTE; SEROLOGY; VACCINATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BONE MARROW; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; ENDEMIC DISEASES; FEMALE; FRANCE; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; NITRIC OXIDE; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 34247484942     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.083     Document Type: Article

References (58)

1. Bettini S., Contini C., Atzeni M.C., and Tocco G. Leishmaniasis in Sardinia. I. Observations on a larval breeding site of Phlebotomus perniciosus, Phlebotomus perfiliewi perfiliewi and Sergentomyia minuta (Diptera: Psychodidae) in the canine leishmaniasis focus of Soleminis (Cagliari). Ann Trop Med Parasitol 80 3 (1986) 307-315
2. Ashford D.A., Badaro R., Eulalio C., et al. Studies on the control of visceral leishmaniasis: validation of the Falcon assay screening test-enzyme-linked immunosorbent assay (FAST-ELISA) for field diagnosis of canine visceral leishmaniasis. Am J Trop Med Hyg 48 1 (1993) 1-8
3. Paranhos-Silva M., Freitas L.A., Santos W.C., Grimaldi G.J., Pontes-de-Carvalho L.C., and Oliveira-dos-Santos A.J. A cross-sectional serodiagnostic survey of canine leishmaniasis due to Leishmania chagasi. Am J Trop Med Hyg 55 1 (1996) 39-44
4. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am J Trop Med Hyg 52 3 (1995) 287-292
5. Gavgani A.S., Hodjati M.H., Mohite H., and Davies C.R. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 360 9330 (2002) 374-379
6. Gramiccia M., Gradoni L., and Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 86 6 (1992) 613-620
7. Vasconcelos I.A., Vasconcelos A.W., Momen H., Grimaldi Jr. G., and Alencar J.E. Epidemiological studies on American leishmaniasis in Ceara State, Brazil. Molecular characterization of the Leishmania isolates. Ann Trop Med Parasitol 82 6 (1988) 547-554
8. Gradoni L., Gramiccia M., Mancianti F., and Pieri S. Studies on canine leishmaniasis control. 2. Effectiveness of control measures against canine leishmaniasis in the Isle of Elba, Italy. Trans R Soc Trop Med Hyg 82 4 (1988) 568-571
9. Palatnik-de-Sousa C.B., dos Santos W.R., Franca-Silva J.C., et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg 65 5 (2001) 510-517
10. Dietze R., Barros G.B., Teixeira L., et al. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Infect Dis 25 5 (1997) 1240-1242
11. Ashford D.A., David J.R., Freire M., et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 59 1 (1998) 53-57
12. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 100 1-2 (2001) 87-103
13. Gramiccia M., and Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 35 11-12 (2005) 1169-1180
14. Garg R., and Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 123 3 (2006) 439-454
15. Phocean Veterinary Study Group on Visceral Leishmaniasis, Dunan S., Frommel D., Monjour L., Ogunkolade B.W., Cruz A., and Quilici M. Vaccination trial against canine visceral leishmaniasis. Parasite Immunol 11 4 (1989) 397-402
16. Lasri S., Sahibi H., Sadak A., Jaffe C.L., and Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 30 5 (1999) 441-449
17. De Luca P.M., Mayrink W., Alves C.R., et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17 9-10 (1999) 1179-1185
18. Antunes C.M., Mayrink W., Magalhaes P.A., et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15 4 (1986) 572-580
19. Genaro O., de Toledo V.P., da Costa C.A., Hermeto M.V., Afonso L.C., and Mayrink W. Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol 14 5 (1996) 503-512
20. Ramiro M.J., Zarate J.J., Hanke T., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
21. Molano I., Alonso M.G., Miron C., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92 1-2 (2003) 1-13
22. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20 27-28 (2002) 3277-3284
23. Nogueira F.S., Moreira M.A., Borja-Cabrera G.P., et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 40 (2005) 4805-4810
24. Prigione I., Facchetti P., Lecordier L., et al. T cell clones raised from chronically infected healthy humans by stimulation with Toxoplasma gondii excretory-secretory antigens cross-react with live tachyzoites: characterization of the fine antigenic specificity of the clones and implications for vaccine development. J Immunol 164 7 (2000) 3741-3748
25. Daryani A., Hosseini A.Z., and Dalimi A. Immune responses against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model. Vet Parasitol 113 2 (2003) 123-134
26. Shams H., Klucar P., Weis S.E., et al. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J Immunol 173 3 (2004) 1966-1977
27. Chenik M., Louzir H., Ksontini H., Dilou A., Abdmouleh I., and Dellagi K. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major. Vaccine (2005)
28. Webb J.R., Campos-Neto A., Ovendale P.J., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 7 (1998) 3279-3289
29. Holzmuller P., Cavaleyra M., Moreaux J., et al. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet Immunol Immunopathol 106 3-4 (2005) 247-257
30. Lemesre J.L., Holzmuller P., Cavaleyra M., Bras-Gonçalves R., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
31. Tonui W.K., Mejia J.S., Hochberg L., et al. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun 72 10 (2004) 5654-5661
32. Rosa R., Rodrigues O.R., Marques C., and Santos-Gomes G.M. Leishmania infantum: soluble proteins released by the parasite exert differential effects on host immune response. Exp Parasitol 109 2 (2005) 106-114
33. Oliva G., Scalone A., Foglia Manzillo V., Gramiccia M., Pagano A., Di Muccio T., et al. Incidence and time course of Leishmania infantum infections examinated by parasitological, serologic, and nested-PCR techniques in a cohort of naïve dogs exposed to three cosecutive transmission seasons. J Clin Microbiol 44 4 (2006) 1318-1322
34. Merlen T., Sereno D., Brajon N., Rostand F., and Lemesre J.L. Leishmania spp: completely defined medium without serum and macromolecules (CDM/LP) for the continuous in vitro cultivation of infective promastigote forms. Am J Trop Med Hyg 60 1 (1999) 41-50
35. Lemesre JL, Methods for the culture in vitro of different stages of tissue parasites. International publication WO 94/26899. 1994.
36. Ravel S., Cuny G., Reynes J., and Veas F. A highly sensitive and rapid procedure for direct PCR detection of Leishmania infantum within human peripheral blood mononuclear cells. Acta Trop 59 3 (1995) 187-196
37. Pinelli E., Gebhard D., Mommaas A.M., et al. Infection of a canine macrophage cell line with leishmania infantum: determination of nitric oxide production and anti-leishmanial activity. Vet Parasitol 92 3 (2000) 181-189
38. Alvar J., Molina R., San Andres M., et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88 4 (1994) 371-378
39. Vexenat J.A., de Castro J.A., Cavalcante R., et al. Visceral leishmaniasis in Teresina, State of Piaui, Brazil: preliminary observations on the detection and transmissibility of canine and sandfly infections. Mem Inst Oswaldo Cruz 89 2 (1994) 131-135
40. Mohebali M., Hamzavi Y., Edrissian G.H., and Forouzani A. Seroepidemiological study of visceral leishmaniasis among humans and animal reservoirs in Bushehr province, Islamic Republic of Iran. East Mediterr Health J 7 6 (2001) 912-917
41. Modabber F. Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 98 Suppl (1989) S49-S60
42. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 89 Suppl 1 (1995) 83-88
43. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14 2 (2001) 229-243
44. Ravindran R., and Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 4 6 (2004) 697-709
45. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza E., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 17-18 (2004) 2234-2243
46. Momeni A.Z., Jalayer T., Emamjomeh M., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17 5 (1999) 466-472
47. Sharifi I., FeKri A.R., Aflatonian M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351 9115 (1998) 1540-1543
48. Khalil E.A., Elhassan A.M., Zijlstra E.E., et al. Safety and immunogenicity of an autoclaved Leishmania major vaccine. East Afr Med J 77 9 (2000) 468-470
49. Sjolander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., and Handman E. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16 20 (1998) 2077-2084
50. Bourdoiseau G., Hugnet C., Papierok G.M., and Lemesre J.L. Canine leishmaniosis due to Leishmania infantum:immunotherapy trials. Bull Acad Vet France 157 (2004) 63-67
51. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernadina W., del Real G., and Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62 1 (1994) 229-235
52. Iniesta V., Gomez-Nieto L.C., Molano I., et al. Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 24 3 (2002) 113-118
53. Molina R., Canavate C., Cercenado E., Laguna F., Lopez-Velez R., and Alvar J. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. Aids 8 2 (1994) 277-279
54. Deplazes P., Smith N.C., Arnold P., Lutz H., and Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 17 9 (1995) 451-458
55. de Oliveira Mendes C., Paraguai de Souza E., Borja-Cabrera G.P., et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine 21 19-20 (2003) 2589-2597
56. Holzmuller P., Bras-Gonçalves R., and Lemesre J.L. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 132 (2006) 19-32
57. Stager S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165 12 (2000) 7064-7071
58. Kemp M., Kurtzhals J.A., Kharazmi A., and Theander T.G. Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol 71 Pt 6 (1993) 583-587